Genentech: Good Medicine
A promising pipeline should mean continued success for the second-largest biotech firm, analysts say.
Biotech giant Genentech's growth story is impressive: Sales of its drugs soared 46% last year, to a whopping $5.5 billion. The company has a solid pipeline of new drugs, including a promising treatment for age-related macular degeneration. And it's testing additional uses for existing blockbusters, expanding their potential market. Analysts expect that the San Francisco-based firm's earnings will grow 30% annually over the next several years.
Genentech focuses on drugs that treat cancer and other serious illnesses, and it has been successful in getting some of its drugs approved for multiple uses. It now hopes that Avastin, which was originally approved in 2004 as a colorectal-cancer drug, will eventually be approved as a treatment for breast, lung and other types of cancer. And it is preparing to file an application with the Food and Drug Administration to expand the use of its breast cancer drug, Herceptin.
The company got two pieces of good news this week: The FDA said its lymphoma drug, Rituxan, could be used to treat certain cases of rheumatoid arthritis (Rituxan is Genentech's biggest seller). Regulators also granted priority review of its macular-degeneration drug, Lucentis, meaning the drug could win approval by the end of June.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
The positive news on Rituxan and Lucentis impressed Standard Poor's analyst Frank DiLorenzo. On Wednesday he raised his Genentech earnings estimates for 2006 and 2007 to $1.83 per share and $2.40 per share, respectively. The stock trades at 47 times the $1.82 per share that analysts, on average, expect the company to earn in 2006, according to Thomson First Call. DiLorenzo thinks the stock, which has soared more than 90% since last March, to $85, is still attractive given the company's earnings potential.
But John Sonnier, an analyst at William Blair Co., thinks the stock (symbol DNA) is too rich. Although he likes Genentech's potential and sees it as "the best growth story in the biotechnology industry," he recommends waiting for a dip in the price before buying. He currently prefers Amgen (AMGN), Genzyme (GENZ) and MedImmune (MEDI). They, too, have strong pipelines, says Sonnier, and their stocks are cheaper. He rates Genentech "market perform."
--Lisa Dixon
-
Stock Market Today: Nasdaq Spirals as Netflix Nosedives
A big earnings boom for credit card giant American Express helped the Dow notch another win.
By Karee Venema Published
-
Get These 40 Earth Day Deals and Discounts
Monday, April 22, is Earth Day. Many of your favorite retailers are celebrating with deals on sustainable products, recycling services, and more
By Kathryn Pomroy Published
-
Stock Market Today: Nasdaq Spirals as Netflix Nosedives
A big earnings boom for credit card giant American Express helped the Dow notch another win.
By Karee Venema Published
-
Stock Market Today: S&P 500, Nasdaq Extend Losing Streaks
The two indexes have closed lower for five straight sessions.
By Karee Venema Published
-
Stock Market Today: Dow Slips After Travelers' Earnings Miss
The property and casualty insurer posted a bottom-line miss as catastrophe losses spiked.
By Karee Venema Published
-
Stock Market Today: Stocks Stabilize After Powell's Rate-Cut Warning
The main indexes temporarily tumbled after Fed Chair Powell said interest rates could stay higher for longer.
By Karee Venema Published
-
Stock Market Today: Stocks Reverse Lower as Treasury Yields Spike
A good-news-is-bad-news retail sales report lowered rate-cut expectations and caused government bond yields to surge.
By Karee Venema Last updated
-
Stock Market Today: Nasdaq Leads as Magnificent 7 Stocks Rise
Strength in several mega-cap tech and communication services stocks kept the main indexes higher Thursday.
By Karee Venema Published
-
Stock Market Today: Stocks Tumble After a Hot Inflation Print
Equities retreated after inflation data called the Fed's rate-cut plans into question.
By Dan Burrows Published
-
Stock Market Today: Stocks End Mixed Ahead of Key Inflation Reading
Equities struggled before tomorrow's big Consumer Price Index report.
By Dan Burrows Published